301 related articles for article (PubMed ID: 8534265)
1. Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings.
Engelhardt G; Bögel R; Schnitzler C; Utzmann R
Biochem Pharmacol; 1996 Jan; 51(1):29-38. PubMed ID: 8534265
[TBL] [Abstract][Full Text] [Related]
2. Meloxicam: influence on arachidonic acid metabolism. Part 1. In vitro findings.
Engelhardt G; Bögel R; Schnitzer C; Utzmann R
Biochem Pharmacol; 1996 Jan; 51(1):21-8. PubMed ID: 8534264
[TBL] [Abstract][Full Text] [Related]
3. Meloxicam inhibits prostaglandin E(2) generation via cyclooxygenase 2 in the inflammatory site but not that via cyclooxygenase 1 in the stomach.
Ogino K; Hatanaka K; Kawamura M; Ohno T; Harada Y
Pharmacology; 2000 Nov; 61(4):244-50. PubMed ID: 11093076
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1.
Ogino K; Hatanaka K; Kawamura M; Katori M; Harada Y
Pharmacology; 1997 Jul; 55(1):44-53. PubMed ID: 9309800
[TBL] [Abstract][Full Text] [Related]
5. Endoscopic comparison of the gastroduodenal safety and the effects on arachidonic acid products between meloxicam and piroxicam in the treatment of osteoarthritis.
Chang DM; Young TH; Hsu CT; Kuo SY; Hsieh TC
Clin Rheumatol; 2001; 20(2):104-13. PubMed ID: 11346221
[TBL] [Abstract][Full Text] [Related]
6. Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4'-isomer.
Pairet M; van Ryn J; Schierok H; Mauz A; Trummlitz G; Engelhardt G
Inflamm Res; 1998 Jun; 47(6):270-6. PubMed ID: 9683035
[TBL] [Abstract][Full Text] [Related]
7. Effects of oxicam inhibitors of cyclooxygenase on oxidative stress generation in rat gastric mucosa. A comparative study.
Villegas I; Martín MJ; La Casa C; Motilva V; De La Lastra CA
Free Radic Res; 2002 Jul; 36(7):769-77. PubMed ID: 12180128
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2.
Engelhardt G
Br J Rheumatol; 1996 Apr; 35 Suppl 1():4-12. PubMed ID: 8630636
[TBL] [Abstract][Full Text] [Related]
10. Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers.
Stichtenoth DO; Wagner B; Frölich JC
J Investig Med; 1997 Feb; 45(2):44-9. PubMed ID: 9084574
[TBL] [Abstract][Full Text] [Related]
11. In vivo effects of meloxicam and aspirin on blood, gastric mucosal, and synovial fluid prostanoid synthesis in dogs.
Jones CJ; Streppa HK; Harmon BG; Budsberg SC
Am J Vet Res; 2002 Nov; 63(11):1527-31. PubMed ID: 12428662
[TBL] [Abstract][Full Text] [Related]
12. Effects of firocoxib, meloxicam, and tepoxalin administration on eicosanoid production in target tissues of healthy cats.
Goodman LA; Torres BT; Reynolds LR; Budsberg SC
Am J Vet Res; 2010 Sep; 71(9):1067-73. PubMed ID: 20807147
[TBL] [Abstract][Full Text] [Related]
13. Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use.
Blain H; Boileau C; Lapicque F; Nédélec E; Loeuille D; Guillaume C; Gaucher A; Jeandel C; Netter P; Jouzeau JY
Br J Clin Pharmacol; 2002 Mar; 53(3):255-65. PubMed ID: 11874389
[TBL] [Abstract][Full Text] [Related]
14. Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state.
Tegeder I; Lötsch J; Krebs S; Muth-Selbach U; Brune K; Geisslinger G
Clin Pharmacol Ther; 1999 May; 65(5):533-44. PubMed ID: 10340919
[TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance.
Engelhardt G; Homma D; Schlegel K; Utzmann R; Schnitzler C
Inflamm Res; 1995 Oct; 44(10):423-33. PubMed ID: 8564518
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers.
van Kraaij DJ; Hovestad-Witterland AH; de Metz M; Vollaard EJ
Br J Clin Pharmacol; 2002 Jun; 53(6):644-7. PubMed ID: 12047490
[TBL] [Abstract][Full Text] [Related]
17. In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenase activity in dogs.
Kay-Mugford P; Benn SJ; LaMarre J; Conlon P
Am J Vet Res; 2000 Jul; 61(7):802-10. PubMed ID: 10895904
[TBL] [Abstract][Full Text] [Related]
18. Mucosal damage induced by preferential COX-1 and COX-2 inhibitors: role of prostaglandins and inflammatory response.
Villegas I; La Casa C; de la Lastra CA; Motilva V; Herrerías JM; Martín MJ
Life Sci; 2004 Jan; 74(7):873-84. PubMed ID: 14659976
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.
Riendeau D; Charleson S; Cromlish W; Mancini JA; Wong E; Guay J
Can J Physiol Pharmacol; 1997 Sep; 75(9):1088-95. PubMed ID: 9365818
[TBL] [Abstract][Full Text] [Related]
20. The effects of meloxicam, indomethacin or NS-398 on eicosanoid synthesis by fresh human gastric mucosa.
Tavares IA
Aliment Pharmacol Ther; 2000 Jun; 14(6):795-9. PubMed ID: 10848664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
